Home   Contact
Universitätsklinikum Tübingen
7th International Tübingen Symposium on Pediatric Solid Tumors
Soft Tissue Sarcoma
September 28 - 29, 2018 — Tübingen, Germany


Friday, 28th September, 2018

08.30 – 08.35 Welcome and Congress opening
  Jörg Fuchs and Rupert Handgretinger (Tuebingen, Germany)
  Session I: Pathology and Epidemiology
  Chair: G. Bisogno (Padana, Italy), R. Handgretinger (Tuebingen, Germany)
08.35 – 08.50 New risk-stratification and new subtypes of RMS
Christian Vokuhl (Kiel, Germany)
08.50 – 09.05 DSRCT in children, adolescents and young adults - characteristics and first-line therapies
Monika Scheer (Stuttgart, Germany)
09.05 – 09-20 Synovial sarcoma in children and AYA: is it time for a composite risk factors classification?
Daniel Orbach (Paris, France)
09.20 – 09.35 Relapses of RMS initially diagnosed in infancy
Monika Sparber-Sauer (Stuttgart, Germany)
09.35 – 09.50 Building data commons to support pediatric cancer research
Samuel Volchenboum (Chicago, USA)
09.50 – 10.00 Molecular characterization of inflammatory myofibroblastic tumors and the first experience of therapy with ALK inhibitor crizotinib in unresectable cases
Amina Suleymanova (Moscow, Russia)
10.00 – 10.30 Coffee Break
  Session II: Clinical trials and International Cooperation
  Chair: T. Klingebiel (Frankfurt, Germany), J. Chisholm (London, UK)
10.30 – 10.45 Rhabdomyosarcoma without borders
Gianni Bisogno (Padova, Italy)
10.45 – 11.00 The Frontline and Relapse in Rhabdomyosarcoma Study: FaR-RMS
Meriel Jenney (Cardiff, UK)
11.00 – 11.15 New developments in NRSTS – The COG experience
Sheri Spunt (Palo Alto, USA)
11.15 – 11.30 New trials on RMS (COG)
Carola Arndt (Rochester, USA)
11.30 – 11.45 Report from INSTRUCT meeting Tuebingen 2018
Ewa Koscielniak (Stuttgart, Germany)
11.45 – 12.00 COG ARST14B1: Targeted Sequencing Validation Study of Pediatric Rhabdomyosarcoma
Javed Khan (Bethesda, USA)
12.00 – 12.10 Tumor necrosis following neoadjuvant chemotherapy for synovial sarcoma: A report from Children’s Oncology Group study ARST0332
Rajkumar Venkatramani (Houston, USA)
12.10 – 13.00 Lunch
  Session III: Tumor Biology, Genetics, Basic Research
  Chair: A. Hayes-Jordan (Houston, USA), S. Gottschalk (Memphis, USA)
13.00 – 13.15 Epigenomic landscape of Rhabdomyosarcoma
Javed Khan (Bethesda, USA)
13.15 – 13.30 From bench to bedside: cellular and molecular origins of RMS
Simone Hettmer (Freiburg, Germany)
13.30 – 13.45 Molecular Pathology of Rhabdomyosarcoma
Janet Shipley (Sutton, UK)
13.45 – 14.00 Rhabdomyosarcoma: an endothelial identity crisis
Mark Hatley (Memphis, USA)
14.00 – 14.15 Immunotherapy of Rhabdomyosarcoma
Javed Khan (Bethesda, USA)
14.15 – 14.30 CAR T-cell therapy for sarcoma
Stephen Gottschalk (Memphis, USA)
14.30 – 14.45 Local tumor irradiation to enhance immunotherapy of Rhabdomyosarcoma
Franziska Eckert (Tuebingen, Germany)
14.45 – 15.00 Harnessing PAX3-FOXO1 biology to identify new vulnerabilities for rhabdomyosarcoma
Beat Schaefer (Zurich, Switzerland)
15.00 – 15.10 Glycine metabolism - a new interface for the treatment of alveolar rhabdomyosarcoma
Anna Adamus (Marburg, Germany)
15.10 – 15.30 Coffee Break
  Session IV: Relapses, Stage IV Disease, New Treatment Options
  Chair: H. Mandeville (Sutton, UK), E. Koscielniak (Suttgart, Germany)
15.30 – 15.45 Relapses in RMS
Carola Arndt (Rochester, USA)
15.45 – 16.00 FaR-RMS relapse study – a framework for the introduction of targeted agents in RMS
Julia Chisholm (London, UK)
16.00 – 16.15 Non-RMS STS: challenges of treatment and new perspectives
Andrea Ferrari (Padova, Italy)
16.15 – 16.30 Metastatic RMS – future perspectives
Thomas Klingebiel (Frankfurt, Germany)
16.30 – 16.45 Novel antibody constructs for the treatment of sarcoma
Rupert Handgretinger (Tuebingen, Germany)
16.45 – 17.00 Clinical trials for RMS/STS – Incorporating novel agents: from biology to clinical application
Susanne Gatz (Sutton, UK)
17.00 – 17.10 Improved Survival After HLA Mismatched versus HLA matched Allogeneic Stem Cell Transplantation Implicates Presence Of A Graft Versus Tumor Effect In Ewing Sarcoma Patients with advanced Disease
Uwe Thiel (Munich, Germany)
17.10 – 17.20 AMORE treatment as salvage treatment in children with relapsed head-neck rhabdomyosarcoma
Bas Vaarwerk (Amsterdam, The Netherlands)

University Children's Hospital Tübingen
Department of Pediatric Surgery and Pediatric Urology
Department of Pediatric Hematology/Oncology